Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.
| Website | http://www.eligo-bioscience.com |
| Revenue | $8.5 million |
| Employees | 47 (35 on RocketReach) |
| Founded | 2014 |
| Address | 29 Rue Du Faubourg Saint-jacques, Paris, Ile de France 75014, FR |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Microbiome Therapeutics, Microbial Therapies, Genome Editing, Microbiome Research, Gut Microbiome, Drug Discovery, Microbial Engineering, Biotechnology, Pharmaceutical Research, Genetic Engineering, Synthetic Biology, Biopharmaceutical, Crispr Technology, Phage Therapy, Probiotics, Immuno-Oncology, Prebiotics |
| Competitors | Novo Nordisk, Amgen, Regeneron, Beam Therapeutics, Intellia Therapeutics, Inc., CRISPR Therapeutics, Avidity NanoMedicines, Editas Medicine, Scribetx, Caribou Biosciences +41 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies |
Looking for a particular Eligo Bioscience employee's phone or email?
The Eligo Bioscience annual revenue was $8.5 million in 2026.
Xavier Duportet is the Co-founder and CEO of Eligo Bioscience.
35 people are employed at Eligo Bioscience.
Eligo Bioscience is based in Paris, Ile de France.
The NAICS codes for Eligo Bioscience are [5417, 541, 54171, 541713, 54].
The SIC codes for Eligo Bioscience are [873, 87].